A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
- Registration Number
- NCT02953639
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 214
- Diagnosis of schizophrenia of any type utilizing the Mini International Neuropsychiatric Interview and diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) direct clinical assessments, family informants and past medical records
- Evidence of stability of symptoms for 3 months at screening, that is, without hospitalizations for schizophrenia or increase in level of psychiatric care due to worsening of symptoms of schizophrenia
- Participants with schizophrenia clinical symptom severity defined by the following: hallucinatory behavior item score less than or equal to (</=) 5 and a delusion item score </= 5 of the PANSS
- Participants on a stable regimen of antipsychotic therapy for at least 3 months at screening and receiving no more than two antipsychotics
- Participants with current DSM-5 diagnosis other than schizophrenia including bipolar disorder, schizoaffective disorder and major depressive disorder
- Clinically significant neurological illness or significant head trauma that affects cognitive function, in the judgment of the principal investigator
- Full scale intelligence quotient </=65 on the Wechsler Abbreviated Scale of Intelligence at screening
- Positive result at screening for hepatitis B, hepatitis C, or human immunodeficiency virus-1 and 2
- Moderate to severe substance use disorder (other than nicotine or caffeine), as defined by the DSM-5, within the last 12 months
- Suicide attempt within 1 year or currently at risk of suicide in the opinion of the Investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks. Basmisanil 80mg BID Basmisanil Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks. Basmisanil 240mg BID Basmisanil Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score Baseline up to Week 24 The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). The MCCB neurocognitive composite T-score is a standardized mean of the six domain scores (excluding social cognition). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher composite T-score represents lower impairment.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 24 in Wechsler Memory Scale Fourth Edition, Verbal Paired Associates (WMS IV-PAL) Score Baseline up to Week 24 The Paired Associates Learning (PAL I and II) of the WMS-IV (Wechsler Memory Scale Fourth edition) is a test of verbal learning and memory that requires the participant to learn novel word pairs. The participant learns the word pairs across learning trials and is asked to recall them immediately (PAL I) or after a 30-minute delay (PAL II). Data is presented here for 3 Scores: VPA I total raw score, VPA II total raw score and VPA II Recognition total raw score. The total raw score ranges for these 3 Scores are 0 to 56, 0 to 14 and 0 to 40 respectively, with larger total raw scores indicating better performance.
Change From Baseline to Week 24 in Ratio Between Trail Making Test (TMT)- Part B and TMT- Part A Scores Baseline up to Week 24 The TMT consists of two parts: Trail Making Part A, which is a part of the standard MCCB and Trail Making Part B additionally included in this study. Circles containing numbers (Part A) or both numbers and letters (Part B) must be sequentially connected. The difference (ratio) in performance between Part A and Part B reflects executive processes and will be used to assess executive functioning including cognitive set shifting abilities and data for this ratio is presented here. Smaller ratio values, hence decreases from baseline (TMT-B/TMT-A ratio values below 1) indicate higher executive functioning capabilities.
Apparent Clearance of Basmisanil at Steady State (CL/F,ss) Pre-dose (hour 0) in Days 7, 14, 42, 84, 168 Population PK model estimated apparent oral clearance of Basmisanil at steady-state.
Maximum Plasma Concentration of Basmisanil at Steady State (Cmax,ss) Pre-dose (hour 0) in Days 7, 14, 42, 84, 168 Population PK model estimated maximum plasma concentration of Basmisanil at steady-state (ss).
Change From Baseline to Week 24 in MCCB Cognitive Domain Scores Baseline up to Week 24 The MCCB is a cognitive battery to assess 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, reasoning and problem solving). Raw scores are converted to age and sex adjusted t-scores which are standardized to normative data, and have a mean of 50 and standard deviation of 10 in the general healthy population. A higher T-score represents lower impairment.
Change From Baseline to Week 24 in Wechsler Memory Scale Fourth Edition, Logical Memory Test (WMS IV-LM) Score Baseline up to Week 24 Logical memory (LM) assesses narrative memory under free-recall conditions. Two short stories are presented orally. The examinee is asked to retell each story from memory immediately after hearing it (LM I). In the delayed condition (LM II), the examinee is asked to retell both stories from the immediate condition (delayed free recall). Data is presented here for 2 Scores: LM I total raw score and LM II total raw score. The total raw score range is from 0 to 50 with larger total raw scores indicating better performance.
Change From Baseline to Week 24 in Personal and Social Performance (PSP) Total Score Baseline up to Week 24 The PSP Total Score is an integer result in the range of 0 to 100. Larger values, hence increases from baseline in the PSP total score, indicate higher social and personal functioning.
Change From Baseline to Week 24 in Schizophrenia Cognition Rating Scale (SCoRS) Total Score Baseline up to Week 24 The main parameter of interest for the Schizophrenia Cognition Rating Scale (SCoRS) is the SCoRS 'Total Score'. The total score range is from 0 to 80 with lower scores indicating better day-to-day functioning.
Change From Baseline to Week 24 in Clinical Global Impression Severity (CGI-S) Rating Baseline up to Week 24 Values for the CGI-S Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
Change From Baseline to Week 24 in Clinical Global Impression Improvement (CGI-I) Rating Baseline up to Week 24 Values for the CGI-I Scale are encoded by the numerical values from 1 to 7 respectively. Higher numerical values represent greater impairment.
Change From Baseline to Week 24 in Schizophrenia Quality of Life Scale (SQLS) Baseline up to Week 24 The SQLS is a patient reported scale consisting of 33 items: 2 domain scores (Cognition \& Vitality Score \[SQLS-CV\] and Psycho-social Score \[SQLS-P\]) as well as a Total score (SQLS-T) are derived. The overall score range is from 0 to 100. On all scales, higher scores represent a lower quality of life.
Apparent Volume of Distribution of Basmisanil at Steady State (Vz/F,ss) Pre-dose (hour 0) in Days 7, 14, 42, 84, 168 Population PK model estimated apparent volume of distribution of Basmisanil at steady-state.
Area Under the Curve of Basmisanil at Steady State (AUC,ss) Pre-dose (hour 0) in Days 7, 14, 42, 84, 168 Population PK model estimated AUC of Basmisanil at steady-state.
Percentage of Participants With Adverse Events (AEs) Baseline up to 4 weeks after the last dose of study drug (up to 28 weeks) An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
Trial Locations
- Locations (37)
Booker, J. Gary, MD, APMC
🇺🇸Shreveport, Louisiana, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Hassman Research Institute
🇺🇸Berlin, New Jersey, United States
Artemis Institute for Clinical Research, LLC
🇺🇸San Diego, California, United States
Woodland Research Northwest, LLC
🇺🇸Rogers, Arkansas, United States
Yale School of Medicine - CT Mental Health Center (CMHC) - Schizophrenia Research Clinic
🇺🇸New Haven, Connecticut, United States
Woodland International Research Group Inc.
🇺🇸Little Rock, Arkansas, United States
ProScience Research Group
🇺🇸Culver City, California, United States
Collaborative Neuroscience Network, Inc.
🇺🇸Garden Grove, California, United States
Synergy Clinical Research
🇺🇸National City, California, United States
NRC Research Institute
🇺🇸Orange, California, United States
iResearch Atlanta
🇺🇸Decatur, Georgia, United States
Innovative Clinical Research, Inc.
🇺🇸Lauderhill, Florida, United States
University of Miami Dept of Psychiatry
🇺🇸Miami, Florida, United States
Meridien Research
🇺🇸Maitland, Florida, United States
CBH Health
🇺🇸Gaithersburg, Maryland, United States
Manhattan Psychiatric Center; Psychopharmacology Research Unit
🇺🇸New York, New York, United States
Behavioral Clinical Research, Inc.
🇺🇸North Miami, Florida, United States
Louisiana Clinical Research, LLC
🇺🇸Shreveport, Louisiana, United States
Alexian Brothers Center for Psychiatric Research
🇺🇸Hoffman Estates, Illinois, United States
Community Clinical Research Center
🇺🇸Anderson, Indiana, United States
Neuro-Behavioral Clinical Research, Inc.
🇺🇸Canton, Ohio, United States
St Louis Clinical Trials
🇺🇸Saint Louis, Missouri, United States
Neurobehavioral Research, Inc.
🇺🇸Cedarhurst, New York, United States
Arch Clinical Trials, LLC
🇺🇸Saint Louis, Missouri, United States
University Hills Clinical Research - Irving;Office of Dr. Knesevich
🇺🇸Irving, Texas, United States
Finger Lakes Clinical Research
🇺🇸Rochester, New York, United States
California Clinical Trials
🇺🇸Glendale, California, United States
Pacific Research Partners, LLC
🇺🇸Oakland, California, United States
Alliance for Wellness, dba Alliance for Research
🇺🇸Long Beach, California, United States
Collaborative Neuroscience Network Inc.
🇺🇸Torrance, California, United States
University Hospitals
🇺🇸Cleveland, Ohio, United States
CNRI - Los Angeles, LLC
🇺🇸Pico Rivera, California, United States
Vantage Clinical Trials
🇺🇸Largo, Florida, United States
Midwest Clinical Research Center
🇺🇸Dayton, Ohio, United States
Pillar Clinical Research LLC
🇺🇸Garland, Texas, United States
Northwest Clinical Research Center
🇺🇸Bellevue, Washington, United States